Skip to content

Ayurveda drug for respiratory infection in children

EFFECT OF HARIDRA KHANDA LOZENGES ON RECURRENT UPPER RESPIRATORY TRACT INFECTIONS IN CHILDREN - HK-RTI

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/08/027318
Enrollment
100
Registered
2020-08-21
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J398- Other specified diseases of upperrespiratory tract

Interventions

Intervention1: Haridra khanda Lozenges: One lozenges (5 gram) thrice daily after food Control Intervention1: Sugar lozenges: One lozenges (5 gram) thrice daily after food

Sponsors

Sri Dharmasthala Manjunatheshwara College of Ayurveda and Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Children between age group of 3 to 8 years. 2. Children will be included in the clinical trial only after remission of acute infections 3. Children with Symptoms mentioned in diagnostic criteria. 4. Children will be selected irrespective of gender, religion and socioeconomic status. 5. Children whose parents are willing to sign the informed assent form

Exclusion criteria

Exclusion criteria: 1. Children with any acute or chronic systemic disorders will not be considered for the trial. 2. Known cases of Bronchial asthma, pulmonary tuberculosis, COPD, Bronchitis, tropical eosinophil or with any other systemic disorder will be excluded

Design outcomes

Primary

MeasureTime frame
Reduction in frequency, duration and severity of upper respiratory tract infecctionsTimepoint: 90 days

Secondary

MeasureTime frame
Improvement in general healthTimepoint: 90 days

Countries

India

Contacts

Public ContactDr Shailaja U

Sri Dharmasthala Manjunatheshwara College of Ayurveda and Hospital

abtittu@gmail.com9480624829

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026